DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5hrn4f/global) has announced the addition of the "Global Epigenetics Market 2014-2018" report to their offering.
The analysts forecast the Global Epigenetics Market to grow at a CAGR of 28.79 percent for the period 2013-2018. Several driving factors and trends will contribute to this growth, all of which will be outlined with detail in this report.
The analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers and challenges, and a number of other factors to provide the most accurate and detailed market research reports possible.
A more specific breakdown of this report's contents is below.
Overview of market share and landscape for the following key geographies:
Overview and impact analysis of:
- 3 Market Drivers
- 3 Market Challenges
- 3 Market Trends
Market Shares and SWOT Analysis for these vendors:
- Celgene Corp.
- Eisai Inc.
- Merck & Co.
Commenting on the report, an analyst from the team said: Along with oncology indications, epigenetic drugs also find application in non-oncology indications such as inflammatory diseases, autoimmune diseases, neurodegenerative disorders, and personalized medicine. These are some of the high growth and emerging areas that are expected to drive the Global Epigenetics market in the future. Current treatments for chronic and degenerative disorders are in many cases inadequate or very expensive. Epigenetic drugs are attractive options for treating such disorders because they manipulate the processes that maintain cells in an abnormal transcriptional state.
For more information visit http://www.researchandmarkets.com/research/5hrn4f/global
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.